CONTACT
+91 80 2808 2808
info@biocon.com

Biocon’s Generic Formulations Facility in Bengaluru completes U.S. FDA Inspection with No 483 observations

  • Posted by: BIOCON

Bengaluru, India, November 12, 2018

“This is to inform you that the U.S. FDA conducted a pre approval inspection of our new Oral Solid Dosage Forms manufacturing facility at Biocon Park/ Bengaluru/ from Nov 05- Nov 09/ 2018. The audit concluded without any observations and no Form 483 was issued. The successful audit of this site reflects our strong commitment to quality and cGMP compliance. N

– Company Spokesperson

Author: BIOCON
Share
Previous Next
Close
Test Caption
Test Description goes like this